Key Documents

View All Documentation

L9664

Loratadine

Name: Loratadine
Brand: SIGMA

≥98% (HPLC), Histamine H1 receptor antagonist, powder

Synonym(s):

4-(8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acid ethyl ester, Loratidine

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₂₂H₂₃N₂O₂Cl

CAS Number:

79794-75-5

Molecular Weight:

382.88

UNSPSC Code:

12352200

PubChem Substance ID:

24278525

NACRES:

NA.77

MDL number:

MFCD00672869

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

200

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

Product Name

Loratadine, ≥98% (HPLC), powder

Quality Level

200

assay

≥98% (HPLC)

form

powder

color

white

solubility

DMSO: soluble 50 mg/mL, H₂O: insoluble

originator

Schering Plough

storage temp.

2-8°C

SMILES string

CCOC(=O)N1CC\C(CC1)=C2/c3ccc(Cl)cc3CCc4cccnc24

InChI

1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3

InChI key

JCCNYMKQOSZNPW-UHFFFAOYSA-N

Gene Information

human ... CYP3A4(1576), HRH1(3269), KCNH1(3756), KCNH2(3757), PTAFR(5724)
rat ... Hrh1(24448)

Description

Biochem/physiol Actions

Loratadine is a non-sedating histamine H1-receptor antagonist. Shown to inhibit the two-pore domain potassium channel K2P18.1 (also called TRESK or KCNK18).

Non-sedating histamine H₁-receptor antagonist.

Features and Benefits

This compound was developed by Schering Plough. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Still not finding the right product?

Explore all of our products under Loratadine

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Antiallergic effects of H1-receptor antagonists.

F M Baroody et al.

Allergy, 55 Suppl 64, 17-27 (2001-04-09)

The primary mechanism of antihistamine action in the treatment of allergic diseases is believed to be competitive antagonism of histamine binding to cellular receptors (specifically, the H1-receptors), which are present on nerve endings, smooth muscles, and glandular cells. This notion

Clinical pharmacology of H1-antihistamines in the skin.

F Estelle R Simons et al.

The Journal of allergy and clinical immunology, 110(5), 777-783 (2002-11-06)

The extent of the distribution of H(1)- antihistamines into the skin and H(1)-antihistamine activity in the skin are clinically relevant in the treatment of allergic skin disorders. In a prospective, randomized, double-blind, parallel-group, multiple-dose study, we gave fexofenadine 180 mg

Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine.

P Deep et al.

Synapse (New York, N.Y.), 34(4), 313-318 (1999-10-26)

The efficacy of amantadine in alleviating motor symptoms of Parkinson's disease may be mediated in part by stimulation of cerebral dopa decarboxylase (DDC) activity, secondary to antagonism of N-methyl-D-aspartate (NMDA) type glutamate receptors. We tested the specific hypothesis that amantadine

View All Related Papers

Global Trade Item Number

SKU	GTIN
L9664-10MG	04061833966860
L9664-50MG	04061832082769